Literature DB >> 30530776

p53 regulates CD46 expression and measles virus infection in myeloma cells.

Anne Lok1,2, Geraldine Descamps1, Benoit Tessoulin1,2, David Chiron1, Marion Eveillard1,3, Catherine Godon3, Yannick Le Bris1,3, Astrid Vabret4, Celine Bellanger1, Laurent Maillet1, Sophie Barillé-Nion1, Marc Gregoire1, Jean-François Fonteneau1, Steven Le Gouill1,2, Philippe Moreau1,2, Frederic Tangy5, Martine Amiot1, Agnes Moreau-Aubry1, Catherine Pellat-Deceunynck1.   

Abstract

In this study, we assessed the sensitivity of myeloma cells to the oncolytic measles virus (MV) in relation to p53 using 37 cell lines and 23 primary samples. We showed that infection and cell death were correlated with CD46 expression, which was associated with TP53 status; TP53 abn cell lines highly expressed CD46 and were preferentially infected by MV when compared with the TP53 wt cell lines (P = .046 and P = .045, respectively). Infection of myeloma cells was fully dependent on CD46 expression in both cell lines and primary cells. In the TP53 wt cell lines, but not the TP53 abn cell lines, activation of the p53 pathway with nutlin3a inhibited both CD46 expression and MV infection, while TP53 silencing reciprocally increased CD46 expression and MV infection. We showed using a p53 chromatin immunoprecipitation assay and microRNA assessment that CD46 gene expression was directly and indirectly regulated by p53. Primary myeloma cells overexpressed CD46 as compared with normal cells and were highly infected and killed by MV. CD46 expression and MV infection were inhibited by nutlin3a in primary p53-competent myeloma cells, but not in p53-deficient myeloma cells, and the latter were highly sensitive to MV infection. In summary, myeloma cells were highly sensitive to MV and infection inhibition by the p53 pathway was abrogated in p53-deficient myeloma cells. These results argue for an MV-based clinical trial for patients with p53 deficiency.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30530776      PMCID: PMC6290095          DOI: 10.1182/bloodadvances.2018025106

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  47 in total

1.  Oncolytic measles virus targets high CD46 expression on multiple myeloma cells.

Authors:  Hooi Tin Ong; Michael M Timm; Philip R Greipp; Thomas E Witzig; Angela Dispenzieri; Stephen J Russell; Kah-Whye Peng
Journal:  Exp Hematol       Date:  2006-06       Impact factor: 3.084

2.  A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines.

Authors:  Jérôme Moreaux; Bernard Klein; Régis Bataille; Géraldine Descamps; Sophie Maïga; Dirk Hose; Hartmut Goldschmidt; Anna Jauch; Thierry Rème; Michel Jourdan; Martine Amiot; Catherine Pellat-Deceunynck
Journal:  Haematologica       Date:  2010-12-20       Impact factor: 9.941

Review 3.  MicroRNAs in the p53 network: micromanagement of tumour suppression.

Authors:  Heiko Hermeking
Journal:  Nat Rev Cancer       Date:  2012-08-17       Impact factor: 60.716

4.  A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice.

Authors:  Chantal Combredet; Valérie Labrousse; Lucile Mollet; Clarisse Lorin; Frédéric Delebecque; Bruno Hurtrel; Harold McClure; Mark B Feinberg; Michel Brahic; Frédéric Tangy
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

5.  Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence.

Authors:  Akinori Takaoka; Sumio Hayakawa; Hideyuki Yanai; Dagmar Stoiber; Hideo Negishi; Hideaki Kikuchi; Shigeru Sasaki; Kohzoh Imai; Tsukasa Shibue; Kenya Honda; Tadatsugu Taniguchi
Journal:  Nature       Date:  2003-07-31       Impact factor: 49.962

6.  The complement receptors CD46, CD55 and CD59 are regulated by the tumour microenvironment of head and neck cancer to facilitate escape of complement attack.

Authors:  Rebecca Kesselring; Annette Thiel; Ralph Pries; Stefan Fichtner-Feigl; Stefan Brunner; Philipp Seidel; Karl-Ludwig Bruchhage; Barbara Wollenberg
Journal:  Eur J Cancer       Date:  2014-06-07       Impact factor: 9.162

7.  Rapid molecular diagnosis of measles virus infection in an epidemic setting.

Authors:  Yanne Michel; Kenda Saloum; Claire Tournier; Béatrice Quinet; Ludovic Lassel; Alice Pérignon; Emmanuel Grimprel; Ricardo Carbajal; Astrid Vabret; François Freymuth; Antoine Garbarg-Chenon; Aurélie Schnuriger
Journal:  J Med Virol       Date:  2013-01-30       Impact factor: 2.327

8.  Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.

Authors:  Antonio Palumbo; Hervé Avet-Loiseau; Stefania Oliva; Henk M Lokhorst; Hartmut Goldschmidt; Laura Rosinol; Paul Richardson; Simona Caltagirone; Juan José Lahuerta; Thierry Facon; Sara Bringhen; Francesca Gay; Michel Attal; Roberto Passera; Andrew Spencer; Massimo Offidani; Shaji Kumar; Pellegrino Musto; Sagar Lonial; Maria T Petrucci; Robert Z Orlowski; Elena Zamagni; Gareth Morgan; Meletios A Dimopoulos; Brian G M Durie; Kenneth C Anderson; Pieter Sonneveld; Jésus San Miguel; Michele Cavo; S Vincent Rajkumar; Philippe Moreau
Journal:  J Clin Oncol       Date:  2015-08-03       Impact factor: 44.544

9.  Activated signal transducers and activators of transcription 3 signaling induces CD46 expression and protects human cancer cells from complement-dependent cytotoxicity.

Authors:  Ralf Buettner; Mei Huang; Tanya Gritsko; Jim Karras; Steve Enkemann; Tania Mesa; Sangkil Nam; Hua Yu; Richard Jove
Journal:  Mol Cancer Res       Date:  2007-08       Impact factor: 5.852

10.  Identification of a core TP53 transcriptional program with highly distributed tumor suppressive activity.

Authors:  Zdenek Andrysik; Matthew D Galbraith; Anna L Guarnieri; Sara Zaccara; Kelly D Sullivan; Ahwan Pandey; Morgan MacBeth; Alberto Inga; Joaquín M Espinosa
Journal:  Genome Res       Date:  2017-09-13       Impact factor: 9.043

View more
  8 in total

Review 1.  Oncolytic viral vectors in the era of diversified cancer therapy: from preclinical to clinical.

Authors:  Chao Tang; Lan Li; Tong Mo; Jintong Na; Zhangbo Qian; Dianfa Fan; Xinjun Sun; Min Yao; Lina Pan; Yong Huang; Liping Zhong
Journal:  Clin Transl Oncol       Date:  2022-05-25       Impact factor: 3.340

2.  Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways.

Authors:  Benoît Tessoulin; Agnès Moreau-Aubry; Géraldine Descamps; Patricia Gomez-Bougie; Sophie Maïga; Alban Gaignard; David Chiron; Emmanuelle Ménoret; Steven Le Gouill; Philippe Moreau; Martine Amiot; Catherine Pellat-Deceunynck
Journal:  J Hematol Oncol       Date:  2018-12-13       Impact factor: 17.388

3.  MeV-Stealth: A CD46-specific oncolytic measles virus resistant to neutralization by measles-immune human serum.

Authors:  Miguel Ángel Muñoz-Alía; Rebecca A Nace; Alexander Tischer; Lianwen Zhang; Eugene S Bah; Matthew Auton; Stephen J Russell
Journal:  PLoS Pathog       Date:  2021-02-03       Impact factor: 6.823

4.  Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy.

Authors:  Valentina Marchica; Valentina Franceschi; Rosanna Vescovini; Paola Storti; Emanuela Vicario; Denise Toscani; Alessia Zorzoli; Irma Airoldi; Benedetta Dalla Palma; Nicoletta Campanini; Eugenia Martella; Cristina Mancini; Federica Costa; Gaetano Donofrio; Nicola Giuliani
Journal:  J Hematol Oncol       Date:  2020-07-11       Impact factor: 17.388

Review 5.  Adenovirus Receptor Expression in Cancer and Its Multifaceted Role in Oncolytic Adenovirus Therapy.

Authors:  Lobke C M Hensen; Rob C Hoeben; Selas T F Bots
Journal:  Int J Mol Sci       Date:  2020-09-17       Impact factor: 5.923

6.  Oncolytic Virus with Attributes of Vesicular Stomatitis Virus and Measles Virus in Hepatobiliary and Pancreatic Cancers.

Authors:  Bolni Marius Nagalo; Camilo Ayala Breton; Yumei Zhou; Mansi Arora; James M Bogenberger; Oumar Barro; Michael B Steele; Nathan J Jenks; Alexander T Baker; Dan G Duda; Lewis Rowland Roberts; Stephen J Russell; Kah Whye Peng; Mitesh J Borad
Journal:  Mol Ther Oncolytics       Date:  2020-08-19       Impact factor: 7.200

Review 7.  CD46 and Oncologic Interactions: Friendly Fire against Cancer.

Authors:  Michelle Elvington; M Kathryn Liszewski; John P Atkinson
Journal:  Antibodies (Basel)       Date:  2020-11-02

8.  Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40.

Authors:  Jessica Wenthe; Sedigheh Naseri; Ann-Charlotte Hellström; Helena Jernberg Wiklund; Emma Eriksson; Angelica Loskog
Journal:  Cancer Gene Ther       Date:  2020-05-01       Impact factor: 5.987

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.